These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38847983)

  • 21. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic landscape of 891 RET fusions detected across diverse solid tumor types.
    Parimi V; Tolba K; Danziger N; Kuang Z; Sun D; Lin DI; Hiemenz MC; Schrock AB; Ross JS; Oxnard GR; Huang RSP
    NPJ Precis Oncol; 2023 Jan; 7(1):10. PubMed ID: 36690680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study.
    Ding Z; Tao X; Deng X; Guo B; Kang J; Wu B; Yang Z; Chen C; Liu P; Zhang Y; Fan Y; Liu Z
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6303-6313. PubMed ID: 36735028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma.
    Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
    Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.
    Henderson YC; Shellenberger TD; Williams MD; El-Naggar AK; Fredrick MJ; Cieply KM; Clayman GL
    Clin Cancer Res; 2009 Jan; 15(2):485-91. PubMed ID: 19147753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
    Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
    J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
    Colombo C; Muzza M; Proverbio MC; Tosi D; Soranna D; Pesenti C; Rossi S; Cirello V; De Leo S; Fusco N; Miozzo M; Bulfamante G; Vicentini L; Ferrero S; Zambon A; Tabano S; Fugazzola L
    Thyroid; 2019 Feb; 29(2):237-251. PubMed ID: 30501571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
    Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
    Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
    [No Abstract]   [Full Text] [Related]  

  • 29. Response to RET-Specific Therapy in
    Dias-Santagata D; Lennerz JK; Sadow PM; Frazier RP; Govinda Raju S; Henry D; Chung T; Kherani J; Rothenberg SM; Wirth LJ
    Thyroid; 2020 Sep; 30(9):1384-1389. PubMed ID: 32292131
    [No Abstract]   [Full Text] [Related]  

  • 30. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
    Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
    Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High endothelial venule-like vessels and lymphocyte recruitment in diffuse sclerosing variant of papillary thyroid carcinoma.
    Low S; Sakai Y; Hoshino H; Hirokawa M; Kawashima H; Higuchi K; Imamura Y; Kobayashi M
    Pathology; 2016 Dec; 48(7):666-674. PubMed ID: 27956273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Invasive properties of papillary thyroid cancer with concurrent BRAF(V600E) mutation and rearranged during transfection proto-oncogene protein expression].
    Meng C; Gao J; Liang J; Liang ZY; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):64-8. PubMed ID: 23469793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma.
    Nannini M; Repaci A; Ricco G; Ianni M; Golemi A; Maiolo V; Ferrari M; Natali F; Rizzini EL; Monari F; Solaroli E; De Leo A; Maloberti T; Pantaleo MA; De Biase D; Tallini G
    Front Oncol; 2022; 12():1042525. PubMed ID: 36578928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.
    Sheu SY; Schwertheim S; Worm K; Grabellus F; Schmid KW
    Mod Pathol; 2007 Jul; 20(7):779-87. PubMed ID: 17464312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
    Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
    Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
    [No Abstract]   [Full Text] [Related]  

  • 36. A Multifocal Pediatric Papillary Thyroid Carcinoma (PTC) Harboring the
    Sisdelli L; Cordioli MIV; Vaisman F; Monte O; Longui CA; Cury AN; Freitas MO; Rangel-Pozzo A; Mai S; Cerutti JM
    Biology (Basel); 2021 Feb; 10(2):. PubMed ID: 33562578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
    Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
    J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse intrathyroidal dissemination of papillary thyroid carcinoma with no stromal fibrosis at presentation: A pattern of aggressive differentiated thyroid carcinoma.
    Fang H; Si Y; Wang C; Gong Q; Liu C; Wang S
    Pathol Res Pract; 2021 Aug; 224():153510. PubMed ID: 34329840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of Wild-Type
    Gandhi MM; Ricciuti B; Harada G; Repetto M; Gildenberg MS; Singh A; Li YY; Gagné A; Wang X; Aizer A; Fitzgerald K; Nishino M; Alessi J; Pecci F; Di Federico A; Fisch A; Drilon A; Nardi V; Sholl L; Awad MM; Rotow J
    JCO Precis Oncol; 2023 Sep; 7():e2300295. PubMed ID: 37972337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.